RNA and genome sequencing in trio approach to find and prioritize gene variants in neurodevelopmental disorders with developmental abnormalities
Official title: Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation
Run by University Hospital, Angers · NCT06762678 · Data updated 2026-11-12
Researchers test RNA sequencing together with trio whole-genome sequencing to help find disease-causing gene variants in people with neurodevelopmental disorders and developmental abnormalities, especially when standard tests have not identified a diagnosis.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 58 (estimated) |
| Sponsor | University Hospital, Angers Government |
| Locations | 7 sites (Angers and 6 other locations) |
| Status | Recruiting |
| Started | November 4, 2025 |
| Main results expected | May 4, 2028 |
| Study ends | May 4, 2028 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT06762678 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adults with neurodevelopmental disorders who have unclear genetic diagnoses after prior chromosomal microarray or exome sequencing, and for whom skin biopsy/ RNA samples are available.
✕Probably not a fit
Patients whose disorders are not caused by detectable genomic or transcriptomic variants may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study uses a multi-omic approach by performing RNA sequencing and trio whole-genome sequencing to identify and prioritize genome variants that may cause neurodevelopmental disorders with malformations. It targets individuals from birth through adulthood who have developmental delays, intellectual disability, autism, or related features and for whom prior genetic testing was inconclusive. The design integrates RNA data to reveal aberrant gene expression and other transcriptomic signals that can guide variant prioritization. The study is centered at French university hospitals and involves collaboration among Angers, Brest, and Le Mans sites. Ethical consent and fibroblast RNA samples are required for research use.
Why it matters
Potential benefit: If successful, the approach could increase diagnostic yield and help tailor management for individuals with neurodevelopmental disorders.
How similar studies have gone: Previous genomic and transcriptomic studies have shown added value in diagnosing complex neurodevelopmental conditions, though trio RNA/DNA approaches are less common and results vary by case.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria : * children or adult without any age limit, with neurodevelopmental disorders defined by : * between 0 and 5 years old with severe developmental delays regarding motor and/or language acquisitions, and/or social communication disorders, * \> 6 years old with intellectual deficiency whatever the severity (with if available, neuropsychological evaluation), with potential associated manifestations such as epilepsy and/or autism, and/or behaviour troubles and/or attention deficit hyperactivity disorder ; * with developmental anomalies and/or dimorphism ; * without any evidence of clinical diagnosis * negative chromosomal microarray and/or exome sequencing * negative fragile X syndrome * skin biopsy feasible or RNA sample extracted from fibroblast culture, available to be used in a research context inside the lab center * consent obtained from the participant or, consent from legal representatives for a minor patient or a patient unable to consent * participant affiliated to the french security regimen or equivalent Exclusion Criteria: * Neurodevelopmental disorders with developmental anomaly from non genetic causes or highly evident diagnosis for which a molecular test is available in routine practices and whose the cost is inferior than the cost of the genome and the RNA sequencing * unwillingness to participate, from the patient or from the legal representatives * Pregnant or lactating women
Where it's running
-
University Hospital of Angers
Angers, France Recruiting -
University Hospital of Brest
Brest, France Recruiting -
Le Mans Hospital Center
Le Mans, France Recruiting -
University Hospital of Rennes
Rennes, France Recruiting -
University Hospital of Nantes
Nantes, France Not yet recruiting -
University Hospital of Tours
Tours, France Not yet recruiting
Show 1 more location
-
Vannes Hospital Center
Vannes, France Not yet recruiting
Study contacts
- Study coordinator: Estelle COLIN, MD, PhD
- Email: estelle.colin@chu-angers.fr
- Phone: 02 41 35 36 37
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Two-week intensive brain-focused therapy program for children with neurodevelopmental and chromosomal conditions
This program will try a two-week, individualized multimodal neurorehabilitation approach for children about 4–12 years old with neurodevelopmental or chromosomal conditions to see if it improves attention, motor skills, communication, and daily functioning.
-
COPCA program for infants at risk of neurodevelopmental disorders
This trial will try the COPCA coaching program with infants under 12 months who are at risk of neurodevelopmental disorders to see if it improves motor development and helps families feel more empowered.
-
Postoperative Rectal Pain Relief With Ear Vagus Nerve Stimulation
This study tests whether stimulating the vagus nerve through an ear-based device can reduce pain after anal or rectal surgery.
-
Perineural Catheter for Hindfoot Surgery Pain Control
This study tests whether a continuous perineural catheter delivering local anesthetic after hindfoot surgery helps with pain more than standard care.
-
Screening for blood clots in adults with acute heart failure
This trial tests whether a guideline-based screening approach can detect pulmonary embolism in adults admitted with acute heart failure.
-
Long-term overwintering on the Kerguelen Islands and its effects on the immune system
This project will test how living as an overwintering team member on the Kerguelen Islands for about a year affects the immune system in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.